Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Thyroid Function and Cardiovascular Disease: The Thy-CVD Cohort (Thy-CVD Cohort)

13 de novembro de 2026 atualizado por: First Affiliated Hospital Xi'an Jiaotong University

Dynamic Thyroid Function Exposure, Cardiovascular Remodeling, and Clinical Outcomes: A Nationwide Multicenter Ambidirectional Cohort Study

The goal of this multicenter observational study is to investigate the relationship between thyroid function, changes in thyroid hormone levels over time, and cardiovascular diseases in adults. The main questions it aims to answer are:

Are different thyroid function states and long-term changes in thyroid hormone levels associated with the risk of major adverse cardiovascular events? How do thyroid function abnormalities affect cardiac structure and function, and can these changes improve after thyroid function returns to normal? Researchers will compare participants with normal thyroid function, subclinical thyroid dysfunction, and overt thyroid dysfunction to evaluate differences in cardiovascular outcomes.The study includes retrospective and prospective cohorts. Researchers will collect thyroid function tests, clinical records, electrocardiograms, echocardiographic findings, treatment information, and long-term cardiovascular outcomes. Participants in the prospective cohort will undergo follow-up, with biological samples collected for exploratory analyses when appropriate and with informed consent. No experimental treatments will be assigned.

Visão geral do estudo

Descrição detalhada

The Thy-CVD Cohort is a nationwide, multicenter, observational study combining retrospective and prospective cohorts to investigate the associations of thyroid function abnormalities and dynamic thyroid hormone exposure with cardiac remodeling and long-term cardiovascular outcomes.The study will enroll adults aged 18 years or older with available thyroid function testing. Participants will be classified into five groups according to thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), and free thyroxine (FT4) levels: euthyroidism, subclinical hyperthyroidism, overt hyperthyroidism, subclinical hypothyroidism, and overt hypothyroidism.The retrospective cohort will include patients evaluated between January 2018 and August 2026. The prospective cohort will enroll participants beginning in September 2026, with standardized longitudinal follow-up planned through 2036.Repeated thyroid function measurements will be used to evaluate the severity, duration, variability, and cumulative burden of thyroid hormone abnormalities, as well as the time required to achieve and maintain normal thyroid function.The primary outcome is the first occurrence of a composite major adverse cardiovascular event, including cardiovascular death, hospitalization for heart failure, myocardial infarction, ischemic or hemorrhagic stroke, and serious arrhythmias requiring clinical intervention.Secondary outcomes include individual cardiovascular events, all-cause mortality, and changes in cardiac structure and function assessed by serial echocardiography. The study will also investigate cardiac reverse remodeling and residual cardiovascular risk after normalization of thyroid function.Exploratory analyses will evaluate associations between thyroid treatment strategies, thyroid function control, and cardiovascular outcomes. Biological samples and clinically obtained residual cardiovascular tissues may be analyzed in selected participants to investigate potential molecular mechanisms.This is an observational study. All clinical treatments and examinations will be determined by treating physicians according to routine clinical practice, without investigator-assigned interventions.

Tipo de estudo

Observacional

Inscrição (Estimado)

10000

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

    • Shaanxi
      • Xi'an, Shaanxi, China, 710061
        • First Affiliated Hospital of Xi'an Jiantong University
        • Contato:
        • Contato:
        • Investigador principal:
          • Guoliang Li
        • Investigador principal:
          • Yang Yan

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

Adults aged 18 years or older who undergo thyroid function testing at the First Affiliated Hospital of Xi'an Jiaotong University and participating medical centers across China. The study population includes individuals with normal thyroid function, subclinical hyperthyroidism, overt hyperthyroidism, subclinical hypothyroidism, and overt hypothyroidism. The retrospective cohort includes eligible patients identified from existing medical records between January 2018 and August 2026. The prospective cohort consecutively enrolls eligible participants beginning in September 2026 for longitudinal follow-up. Thyroid function status, cardiovascular risk factors, treatment information, cardiac imaging findings, and clinical outcomes will be collected. Biological sample availability is not required for enrollment.

Descrição

Inclusion Criteria:

  1. Adults aged 18 years or older.
  2. At least one thyroid function assessment, including thyroid-stimulating hormone (TSH) and free triiodothyronine (FT3) and/or free thyroxine (FT4).
  3. Available and traceable clinical information, including demographic characteristics, medical history, laboratory findings, imaging results, or follow-up records.
  4. Thyroid functional status can be determined from available thyroid function measurements and corresponding laboratory reference ranges.
  5. For the prospective cohort, participants must provide informed consent for study participation and be willing to undergo longitudinal follow-up.

Exclusion Criteria:

  1. Thyroid functional status cannot be reliably determined from available clinical and laboratory data.
  2. Key clinical information is substantially incomplete or unreliable, preventing adequate assessment of the primary outcome.
  3. No reliable information is available to ascertain cardiovascular outcomes or vital status after baseline.
  4. Duplicate enrollment; only the first eligible record will be retained.
  5. Other circumstances that, in the investigator's judgment, make the individual unsuitable for study participation or long-term follow-up.

Biospecimen availability is not required for enrollment. Participants without available biological samples remain eligible if they meet the other inclusion and exclusion criteria.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: COHORT
  • Perspectivas de Tempo: OTHER

Coortes e Intervenções

Grupo / Coorte
Retrospective Cohort

Adults aged 18 years or older who underwent thyroid function testing at participating centers between January 2018 and August 2026 will be retrospectively identified through existing electronic health records. Clinical data, including thyroid function measurements (TSH, FT3, and FT4), thyroid disease diagnoses, treatment history, cardiovascular risk factors, electrocardiographic and echocardiographic findings, and clinical outcomes, will be collected from existing medical records and follow-up databases. Participants will be classified according to baseline thyroid function status and longitudinal thyroid hormone exposure patterns, where repeated measurements are available. No additional clinical interventions will be performed.

Prospective Cohort

Adults aged 18 years or older undergoing thyroid function testing at participating centers will be prospectively enrolled beginning in September 2026 and followed longitudinally. Baseline and follow-up data will include thyroid function measurements (TSH, FT3, and FT4), thyroid disease characteristics, treatment information, cardiovascular risk factors, electrocardiographic and echocardiographic findings, and clinical outcomes. Repeated thyroid function assessments will be used to characterize longitudinal hormone exposure patterns and their associations with cardiac remodeling and cardiovascular events. Biological samples may be collected with informed consent for exploratory analyses. Clinical management will follow routine medical practice without investigator-assigned interventions.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Time to First Major Adverse Cardiovascular Event (MACE)
Prazo: Baseline; 3, 6, 12, 24, 36, 48, and 60 months; annually thereafter through 10 years of follow-up.

Time from baseline to the first occurrence of major adverse cardiovascular events (MACE), defined as the composite of cardiovascular death, hospitalization for heart failure, myocardial infarction, ischemic or hemorrhagic stroke, or serious arrhythmia requiring clinical intervention, including new-onset atrial fibrillation and sustained ventricular arrhythmias. The outcome will be measured as time to the first qualifying event in days. Events will be identified through medical records, hospitalizations, clinical follow-up, and available death records. Only the first qualifying event per participant will be counted.

Baseline; 3, 6, 12, 24, 36, 48, and 60 months; annually thereafter through 10 years of follow-up.

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
New-Onset Atrial Fibrillation
Prazo: Baseline; 3, 6, 12, 24, 36, 48, and 60 months; annually thereafter through 10 years of follow-up.

Number of participants without documented atrial fibrillation at baseline who develop newly diagnosed atrial fibrillation during follow-up. Atrial fibrillation will be identified by 12-lead electrocardiography, ambulatory electrocardiographic monitoring, or documented clinical diagnoses in medical records. The outcome will be reported as the number of participants with newly diagnosed atrial fibrillation.

Baseline; 3, 6, 12, 24, 36, 48, and 60 months; annually thereafter through 10 years of follow-up.
Heart Failure Events
Prazo: Baseline; 3, 6, 12, 24, 36, 48, and 60 months; annually thereafter through 10 years of follow-up.

Number of participants experiencing clinically documented heart failure events during follow-up. Heart failure will be identified through physician-documented diagnoses, hospitalization records, and available clinical assessments. The outcome will be reported as the number of participants with documented heart failure events.

Baseline; 3, 6, 12, 24, 36, 48, and 60 months; annually thereafter through 10 years of follow-up.
Coronary Artery Disease Events
Prazo: Baseline; 3, 6, 12, 24, 36, 48, and 60 months; annually thereafter through 10 years of follow-up.

Number of participants experiencing clinically documented coronary artery disease events during follow-up. Events will be identified from medical records, clinical diagnoses, coronary angiography, and available coronary imaging reports. The outcome will be reported as the number of participants with documented coronary artery disease events.

Baseline; 3, 6, 12, 24, 36, 48, and 60 months; annually thereafter through 10 years of follow-up.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Guoliang Li, First Affiliated Hospital Xi'an Jiaotong University
  • Investigador principal: Yang Yan, First Affiliated Hospital Xi'an Jiaotong University

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

11 de novembro de 2026

Conclusão Primária (Estimado)

1 de agosto de 2046

Conclusão do estudo (Estimado)

1 de agosto de 2046

Datas de inscrição no estudo

Enviado pela primeira vez

8 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

13 de novembro de 2026

Primeira postagem (Real)

19 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

19 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

13 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever